In this episode, Gain Therapeutics CEO Eric Richman discusses some of the challenges facing drug developers targeting Parkinson's disease and the novel computational approach Gain is taking to serve this unmet medical need.
In this episode, Gain Therapeutics CEO Eric Richman discusses some of the challenges facing drug developers targeting Parkinson's disease and the novel computational approach Gain is taking to serve this unmet medical need.
